Appropriate dose of regorafenib based on body weight of colorectal cancer patients: A retrospective cohort study

Previous randomized studies have shown a survival benefit of using regorafenib but a high rate of adverse events in unresectable colorectal cancer patients. To reduce these adverse events and improve the tolerability, we examined the appropriate dose of regorafenib based on body weight.